Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Lymphocytic Leukemia Stories

2013-10-31 08:32:19

Management will discuss pivotal trial plans for its drug candidate Iomab(TM)-B and its potential as a new treatment paradigm for certain blood cancers NEW YORK, Oct. 31, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update and Virtual Roadshow to discuss the current plans...

2013-10-22 16:24:35

Nine Innovative Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Oct. 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive The New Idea Award--a grant program designed to identify novel research strategies with high potential for significant impact on the future of blood cancer treatments. Specifically, this program supports academic researchers with innovative ideas for substantially different...

2013-10-21 13:36:53

Study led by St. Jude Children's Research Hospital finds an inherited gene variation -- more common among Hispanic Americans -- is tied to increased risk of developing a high-risk form of pediatric leukemia Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome. The study appears today in the online...

2013-10-17 08:29:36

Free, Live Telephone/Web Education Program Featuring International Pediatric Acute Lymphoblastic Leukemia Experts Susan R. Rheingold, M.D. and Cara L. Simon, Ph.D., APRN, CPNP (Live Spanish interpretation also offered) WHITE PLAINS, N.Y., Oct. 17, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking...

2013-10-15 12:32:15

LLS Specialized Center of Research Program Surpasses $285 Million Mark WHITE PLAINS, N.Y., Oct. 15, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded four new grants through its prestigious Marshall A. Lichtman Specialized Center of Research (SCOR) research initiative, bringing the program's total funding to $285 million since its inception in 2000. The innovative SCOR program funds teams of researchers representing different disciplines...

2013-10-07 04:20:52

AMSTERDAM, October 7, 2013 /PRNewswire/ -- ~ Technology transfer successfully completed and manufacturing underway ~ Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma's...

2013-09-03 08:28:36

CAMBRIDGE, Mass., Sept. 3, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/310,157 "SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS" with claims covering the novel compound EPZ-5676. Epizyme's EPZ-5676 is a...

2013-08-16 08:23:55

Small Molecule Inhibitor of the DOT1L Histone Methyltransferase (HMT) designated for Acute Leukemias with MLL Rearrangements (MLL-r) CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for...

2013-08-06 12:24:51

BEL AIR, Md., Aug. 6, 2013 /PRNewswire-USNewswire/ -- The following is being released by the Matthews Foundation: (Photo: http://photos.prnewswire.com/prnh/20130806/DC59536) WHAT: All-ages Benefit Concert to Support Matthews Foundation and Acute Lymphoblastic Leukemia. In loving memory of Anthony J. Constantino WHEN: Sunday, Aug. 18, 2:00 p.m. to 8:00 p.m. WHERE: Looney's Pub North - 312 S. Main Street, Bel Air, MD 21014 DETAILS: Some of the Baltimore area's most popular...

2013-07-31 16:27:54

SUNNYVALE, Calif., July 31, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its quarter ended June 30, 2013. Financial Results for the Three and Six Months Ended June 30, 2013 Non-GAAP net income reported for the quarter ended June 30, 2013 was $19.2 million, or $0.26 and $0.25 net income per basic and diluted share, respectively, compared to non-GAAP net loss of $15.1 million, or $0.22 net loss...